Company intelligence / Profile preview
Laxxon Medical
New York, New York, United Stateslaxxonmedical.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Positive pilot PK study results for Advanced Levodopa/Carbidopa Asset for Parkinson's Disease (LXM.5) showing 80% bioavailability increase compared to competing products. Also positive pilot PK data for oral GLP-1 dosage form with 10-fold increase in bioavailability over competing products.
- Therapeutic areas
- Neurology
- Modalities
- Oral drug delivery formstransdermal dosage formsimplantable dosage forms
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Adare Pharma Solutions
Beyond the preview
Go deeper on Laxxon Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Laxxon Medical.